Raytheon awarded $71 million in Navy contracts for missile systems
CAMBRIDGE, MA — On April 1, 2025, John M. Evans, CEO of Beam Therapeutics Inc . (NASDAQ:BEAM), sold 30,663 shares of the company’s common stock, according to a recent SEC filing. The shares were sold at a weighted average price of $18.3506, generating a total of $562,684. This transaction was part of a pre-established Rule 10b5-1 trading plan, which Evans adopted in May 2023 to cover tax withholding obligations linked to the vesting of restricted stock units.
Following this sale, Evans holds 986,249 shares directly and an additional 103,000 shares indirectly through the John M. Evans, III 2018 Irrevocable Trust. The sale was executed in multiple transactions, with prices ranging from $17.76 to $18.38 per share. The $1.34 billion market cap company maintains a strong liquidity position with a current ratio of 4.82 and an overall Financial Health score of "FAIR" on InvestingPro.
This latest move comes as Beam Therapeutics continues to focus on advancing its pipeline of gene-editing therapies. InvestingPro analysis suggests the stock is currently undervalued, with comprehensive insights available in the Pro Research Report, including detailed financial metrics and growth projections.
In other recent news, Beam Therapeutics has reported several significant developments concerning its gene editing therapies. The company received approval from the U.S. Food and Drug Administration (FDA) for its investigational new drug application for BEAM-302, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD). This approval allows Beam to advance its clinical trials, which are currently in the Phase 1/2 stage. Additionally, Beam’s recent announcement of positive data from these trials has led Citi to raise its price target for the company to $64, maintaining a Buy rating. The data showed promising results, including dose-dependent increases in total serum Alpha-1 Antitrypsin levels and a clean safety profile with no serious adverse events reported.
Meanwhile, BofA Securities upgraded Beam Therapeutics’ stock rating to Buy, setting a price target of $42, citing positive data on BEAM-302 and a decreased risk associated with the company’s gene editing platform. Bernstein SocGen Group has maintained its Outperform rating and a $37 price target, expressing confidence in the company’s prospects despite recognizing challenges due to competitor data releases. The firm anticipates further positive data on Beam’s lung and liver treatments in the coming year.
The recent $500 million follow-on offering by Beam is expected to extend its cash runway into 2028, further supporting its pipeline development. Analysts from Citi have noted an increased probability of success for BEAM-302, raising it to 60%, and highlighted the validation of Beam’s proprietary lipid nanoparticle technology. These developments underscore Beam Therapeutics’ ongoing efforts in advancing precision genetic treatments and its potential impact on the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.